The medical community has received encouraging data on the prospects of treating aggressive forms of oncology. During an international clinical trial, the experimental drug amivantamab showed high efficacy against head and neck cancer, which previously did not respond to standard therapies.
The trials, covering 11 countries, included 102 patients with diagnoses resistant to chemotherapy and immunotherapy. The results were significant: 43 people experienced a reduction or complete disappearance of tumors.
Complete remission and mechanism of action
Cases of complete disease regression are particularly noteworthy. In 15 participants of the study, doctors noted the complete disappearance of tumors. Another 28 patients experienced a significant reduction in tumor size. This indicates that the drug is capable of dealing with diseases that were considered incurable at late stages.
The efficacy of amivantamab is due to its multi-component action. The drug works in three key areas:
- Blocks molecular mechanisms responsible for the growth and division of cancer cells.
- Prevents the development of tumor resistance to ongoing treatment.
- Activates the body's own immune system to attack tumors.
An important aspect of the study was the tolerability of the drug. Researchers noted that most side effects were classified as mild or moderate, making the therapy potentially accessible to a wide range of patients.
Global development prospects
Detailed results of the clinical trials will be presented at the American Society of Clinical Oncology (ASCO) conference, which will be held in Chicago. The drug was developed by pharmaceutical giant Johnson & Johnson. Currently, amivantamab is undergoing dozens of clinical trials not only for the treatment of head and neck cancer, but also for fighting other types of oncology, including lung, colon, stomach, and brain cancer.